Troy Schooley, CEO of P3R, is stepping down from his role, the organization announced on Thursday. Here's his next move.
Biogen will acquire San Diego's RayThera for up to $1B, expanding its immunology pipeline with early-stage anti-inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results